Cargando…

Issuing bonds during the Covid-19 pandemic: Was there an ESG premium?()

We rely on the ESG ratings assigned by four distinct agencies (MSCI, Refinitiv, Robeco, and Sustainalytics) to study the link between ESG scores and firms’ cost of debt financing during the Covid-19 pandemic. We document the existence of a statistically and economically significant ESG premium, i.e....

Descripción completa

Detalles Bibliográficos
Autor principal: Ferriani, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098047/
https://www.ncbi.nlm.nih.gov/pubmed/37070084
http://dx.doi.org/10.1016/j.irfa.2023.102653
_version_ 1785024709740462080
author Ferriani, Fabrizio
author_facet Ferriani, Fabrizio
author_sort Ferriani, Fabrizio
collection PubMed
description We rely on the ESG ratings assigned by four distinct agencies (MSCI, Refinitiv, Robeco, and Sustainalytics) to study the link between ESG scores and firms’ cost of debt financing during the Covid-19 pandemic. We document the existence of a statistically and economically significant ESG premium, i.e. better rated companies access debt at a lower cost. Despite some differences across rating agencies, this result is robust to additional controls for the issuer’s credit standing as well as several bond and issuer’s characteristics. We find that this effect is mainly driven by firms domiciled in advanced economies, whereas creditworthiness considerations prevail for firms in emerging markets. Lastly, we show that the lower cost of capital for highly rated ESG firms is explained both by investors’ preference for more sustainable assets and by risk-based considerations unrelated to firms’ creditworthiness, such as exposure to climate change risks.
format Online
Article
Text
id pubmed-10098047
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-100980472023-04-13 Issuing bonds during the Covid-19 pandemic: Was there an ESG premium?() Ferriani, Fabrizio Int Rev Financ Anal Article We rely on the ESG ratings assigned by four distinct agencies (MSCI, Refinitiv, Robeco, and Sustainalytics) to study the link between ESG scores and firms’ cost of debt financing during the Covid-19 pandemic. We document the existence of a statistically and economically significant ESG premium, i.e. better rated companies access debt at a lower cost. Despite some differences across rating agencies, this result is robust to additional controls for the issuer’s credit standing as well as several bond and issuer’s characteristics. We find that this effect is mainly driven by firms domiciled in advanced economies, whereas creditworthiness considerations prevail for firms in emerging markets. Lastly, we show that the lower cost of capital for highly rated ESG firms is explained both by investors’ preference for more sustainable assets and by risk-based considerations unrelated to firms’ creditworthiness, such as exposure to climate change risks. Elsevier Inc. 2023-07 2023-04-13 /pmc/articles/PMC10098047/ /pubmed/37070084 http://dx.doi.org/10.1016/j.irfa.2023.102653 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ferriani, Fabrizio
Issuing bonds during the Covid-19 pandemic: Was there an ESG premium?()
title Issuing bonds during the Covid-19 pandemic: Was there an ESG premium?()
title_full Issuing bonds during the Covid-19 pandemic: Was there an ESG premium?()
title_fullStr Issuing bonds during the Covid-19 pandemic: Was there an ESG premium?()
title_full_unstemmed Issuing bonds during the Covid-19 pandemic: Was there an ESG premium?()
title_short Issuing bonds during the Covid-19 pandemic: Was there an ESG premium?()
title_sort issuing bonds during the covid-19 pandemic: was there an esg premium?()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098047/
https://www.ncbi.nlm.nih.gov/pubmed/37070084
http://dx.doi.org/10.1016/j.irfa.2023.102653
work_keys_str_mv AT ferrianifabrizio issuingbondsduringthecovid19pandemicwasthereanesgpremium